AMGNAmgenFinished
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Gastric Cancer · Gastroesophageal Junction Adenocarcinoma
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jun 2025, none posted yet
Counts until it's fixed
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score12
Score over time
- Stage
- Phase 3
- Patients
- 547 (final count)
- Started
- Mar 7, 2022
- Main results expected
- Jun 20, 2025
- Fully finished
- Apr 26, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival
Measured over: Up to approximately 3.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-06-20, no fading
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05052801 · record last updated 2026-10-23 · checked 2026-11-09 15:42 UTC